Adjuvant Capital Reduces AN2 Therapeutics Stake, Files SC 13G/A
Ticker: ANTX · Form: SC 13G/A · Filed: Feb 9, 2024 · CIK: 1880438
Complexity: simple
Sentiment: bearish
Topics: institutional-ownership, ownership-change, amendment, biotech
TL;DR
**Adjuvant Capital cut its AN2 Therapeutics stake, signaling a potential shift in institutional confidence.**
AI Summary
Adjuvant Global Health Technology Fund, L.P. filed an amended SC 13G/A on February 9, 2024, indicating a change in their ownership of AN2 Therapeutics, Inc. common stock as of December 31, 2023. This filing, an amendment to a previous Schedule 13G, signals that Adjuvant Capital is no longer required to report its holdings under Rule 13d-1(b) or (c), likely due to a decrease in their beneficial ownership below the 5% threshold. This matters to investors because it suggests a significant institutional holder has reduced its stake, which could be interpreted as a loss of confidence or a strategic portfolio adjustment.
Why It Matters
This filing indicates a major institutional investor, Adjuvant Global Health Technology Fund, has reduced its stake in AN2 Therapeutics, which could signal a shift in their investment thesis or a strategic portfolio rebalancing.
Risk Assessment
Risk Level: medium — A significant institutional investor reducing its stake can sometimes precede further stock price declines if other investors interpret it negatively.
Analyst Insight
An investor might consider this a signal to re-evaluate their position in AN2 Therapeutics, potentially looking for other fundamental reasons for the reduction in stake or monitoring for further institutional selling.
Key Players & Entities
- Adjuvant Global Health Technology Fund, L.P. (company) — the reporting person who filed the SC 13G/A
- AN2 Therapeutics, Inc. (company) — the subject company whose securities are being reported
- Adjuvant Capital GP, L.P. (company) — a group member associated with the reporting person
- Adjuvant Capital Management, L.L.C. (company) — a group member associated with the reporting person
- December 31, 2023 (date) — the date of the event requiring the filing
Forward-Looking Statements
- AN2 Therapeutics' stock price may experience downward pressure due to the perceived lack of institutional confidence. (AN2 Therapeutics, Inc.) — medium confidence, target: Q1 2024
- Other institutional investors might re-evaluate their positions in AN2 Therapeutics following this disclosure. (Institutional Investors) — low confidence, target: Q2 2024
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G, filed under Rule 13d-1(d) of the Securities Exchange Act of 1934.
Who is the reporting person in this filing?
The reporting person is Adjuvant Global Health Technology Fund, L.P.
What is the subject company whose securities are being reported?
The subject company is AN2 Therapeutics, Inc., with the CUSIP number 037326105 for its Common Stock, $0.00001 par value per share.
What was the date of the event that required this filing?
The date of the event which required the filing of this statement was December 31, 2023.
Which rule under the Securities Exchange Act of 1934 is checked for this filing?
The appropriate box checked for this Schedule is Rule 13d-1(d), indicating it's an amendment to a previous filing under different rules.
Filing Stats: 1,660 words · 7 min read · ~6 pages · Grade level 8.9 · Accepted 2024-02-09 07:06:25
Key Financial Figures
- $0.00001 — Inc. (Name of Issuer) Common Stock, $0.00001 par value per share (Title of Class o
Filing Documents
- d691268dsc13ga.htm (SC 13G/A) — 81KB
- d691268dex991.htm (EX-99.1) — 6KB
- 0001193125-24-029181.txt ( ) — 89KB
SIGNATURES
SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: February 9, 2024 ADJUVANT GLOBAL HEALTH TECHNOLOGY FUND, L.P. By: Adjuvant Capital GP, L.P., its sole general partner, By: Adjuvant Capital Management, L.L.C., its sole general partner, By: /s/ Kabeer Aziz Name: Kabeer Aziz Title: Vice President and Secretary ADJUVANT GLOBAL HEALTH TECHNOLOGY FUND DE, L.P. By: Adjuvant Capital GP, L.P., its sole general partner, By: Adjuvant Capital Management, L.L.C., its sole general partner, By: /s/ Kabeer Aziz Name: Kabeer Aziz Title: Vice President and Secretary ADJUVANT CAPITAL GP, L.P. By: Adjuvant Capital Management, L.L.C., its sole general partner, By: /s/ Kabeer Aziz Name: Kabeer Aziz Title: Vice President and Secretary ADJUVANT CAPITAL MANAGEMENT, L.L.C. By: /s/ Kabeer Aziz Name: Kabeer Aziz Title: Vice President and Secretary Page 8 of 9